Saphnelo recommended for approval in EU by CHMP for treatmen

AstraZeneca’s Saphnelo (anifrolumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy for the

Related Keywords

Canada , Japan , Cambridge , Cambridgeshire , United Kingdom , Manchester , Ian Bruce , Astrazeneca Saphnelo , Medarex Inc , University Of Manchester , Nasdaq , Company On Twitter Astrazeneca , Astrazeneca , European Union , European Medicines Agency , Committee For Medicinal Products Human Use , Medicinal Products , Human Use , Executive Vice President , Bristol Myers Squibb , Uncontrolled Lupus , Interferon Pathway , Based Composite Lupus Assessment , New England Journal , Lancet Rheumatology , Rare Diseases ,